BioSpace News Archive

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into separate, privately-negotiated exchange agreements with certain holders of its 5.25% Convertible Senior Notes due 2021 under which such holders have agreed to exchange an aggregate principal amount of $62.55 million of Notes in exchange for aggregate consideration consisting of $41.03 million in cash

Francis S. Collins, M.D., Ph.D., the 16th Director of the National Institutes of Health (NIH) will deliver brief remarks and engage in a virtual Q&A on the latest COVID-19 therapeutic and vaccine developments and how the agency is helping to promote research and engagement in communities hardest hit by COVID-19 at a National Press Club Virtual Newsmaker presentation on Monday, September 28 at 3:30 p.m.

Samsung Biologics (207940.KS) and Kanaph Therapeutics have entered into a strategic partnership to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.

The U.S. Food and Drug Administration issued an emergency use authorization for the first serology point-of-care test for COVID-19.

Centene Corporation announced that it has priced its previously announced underwritten public offering of $2,200,000,000 aggregate principal amount of 3.00% senior notes due 2030.

Gilead Sciences, Inc. announced the pricing of senior unsecured notes in an aggregate principal amount of $7.25 billion, in an underwritten, registered public offering, consisting of seven tranches

Zogenix, Inc. announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real- world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, provided an update on its corporate progress and reported its financial results for the three and six months ended June 30, 2020.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology Company, announced today that the Company has appointed Gilad Yron to the position of Chief Business Officer.

Ocutrx Vision Technologies, LLC, an augmented/extended reality manufacturing company, announced today the issuance of its third and fourth awarded patents by the U.S. Patent & Trademark Office.